Aaron Cowley and Helena Cowley conducting research in search of the optimal enzyme-based product for oxalate reduction. 

Aaron Cowley and Helena Cowley conducting research in search of the optimal enzyme-based product for oxalate reduction. 

Our Story

Captozyme Co-Founders Aaron Cowley and Qing-Shan Li started working together in the mid-2000s at a biotechnology company researching solutions for reducing oxalate.  They realized the incredible impact their work could have on quality of life for people struggling to maintain their health and decided to add ‘entrepreneur’ to their list of impressive credentials:  Cowley’s Ph.D. in inorganic chemistry and an MBA, and Li’s Ph.D. in biochemical engineering.  When Helena Cowley joined the newly established venture she brought her own wealth of passion and experience to the table, with both a master’s degree in bioengineering and an MBA.          

To support their dream, the Cowleys and Li began lending their expertise in biochemical engineering and enzymes to develop pharmaceuticals, medical foods and food additives, and provide consultation services to an impressive and growing list of clients.

Meanwhile, the trio had embarked on a 10-year journey to research and develop the optimal enzyme-based product for oxalate reduction, hoping to deliver a product that promote kidney health and frees sufferers of nutritional limitations.

Their shared passion for making a difference drove the scientists to study and taste hundreds of natural substances from plants to algae, often foraging in the woods. Combining their experience and research, today Captozyme is at the forefront of finding safe and effective approaches for kidney health.